Table 1.
Description of studies included in the systematic review
| Study | Condition | Country | Number* Included/Completed |
Number of women (%) | Mean age (years) | Caucasian (%) | Clinical setting | Method | Relevant medication | Funding from pharmaceutical company | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Morss et al39 | Schizophrenia | USA | 33 | 2 (6) | 43 | 75 | Inpatient and outpatient | VAS, PC, SG | Antipsychotics | Yes | Side effects |
| Revicki et al48 | Schizophrenia | UK, USA | 49 | 12 (24.5) | 39 | 94 | Outpatient | Rating scale, PC | Psychopharmacological treatment | Yes | Symptoms, process related, functioning |
| Lenert et al46 | Schizophrenia, schizoaffective disorder | USA | 22 | Not reported | 46 | Not reported | Outpatient | VAS, PC, SG | Antipsychotics | No | Side effects |
| Lee et al44 | Schizophrenia | USA | 20 | 12 (55) | Range: 18–60 | 40 | Mental health centre | VAS, SG | Antipsychotics | Yes | Symptoms, side effects |
| Lenert and Kaplan28 | Schizophrenia | USA | 148 | 49 (33) | 98%≤60 | Not reported† | Centres and practice organisations | VAS, SG | Antipsychotics | Yes | Symptoms, side effects |
| Shumway45 | Schizophrenia | USA | 50 | 17 (34.5) | 42 | 69 | Outpatient | Rating scales, CA | Antipsychotics | No | Symptoms, functioning, side effects, other |
| Briggs et al40 | Schizophrenia, schizoaffective disorder | UK | 50/49 | 27 (55) | 44 | 94 | Outpatient | VAS, TTO | Antipsychotics | Yes | Symptoms, side effects, other |
| Bridges et al36 | Schizophrenia | USA, Germany | 105/97 | 50‡ | 44 | Not reported | Outpatient | Self-explicated method | Prescribed treatments | Yes | Symptoms, functioning, process related, other |
| Kinter et al42 | Schizophrenia | USA, Germany, New Zealand | 101/100 | 40 (40) | 43/42 | Not reported | Outpatient | CA | Antipsychotics | Yes | Symptoms, functioning, side effects, other |
| O'Brien et al38 | Mild or moderate depression | Canada | 95 | 69 (73) | 41 | Not reported | Outpatient | VAS, WTP | Antidepressants | Yes | Side effects, costs |
| Revicki and Wood47 | Major depressive disorder | USA, Canada | 70 | 54 (77) | 42 | Not reported | Outpatient | VAS§, SG | Antidepressants | Yes | Symptoms, side effects |
| Morey et al41 | Major depressive disorder | USA | 104 | 77 (74) | 40 | Not reported | Outpatient | WTP | Antidepressants | No | Side effects, costs, process related |
| Zimmer-mann et al35 | Depression | Germany | 255/227 | 140 (62) | Not reported¶ | Not reported | Outpatient | CA | Antidepressants | Yes | Symptoms, functioning, side effects, process related |
| Revicki et al43 | Bipolar disorder type I | USA | 96/92 | 51 (55.5) | 42 | 92 | Community hospital, research centre and health centre | VAS, SG | Mood stabilisers, antipsychotics | Yes | Symptoms, side effects, process related |
| Johnson et al34 | Bipolar disorder | USA | 469 | 295 (63) | 43 | 86 | Members of a web-based chronic illness panel | DCE** | Bipolar medications | Yes | Symptoms, side effects |
| Glenngård et al37 | ADHD | Sweden, Denmark, Norway | 116 | 66 (57) | Not reported | Not reported | Centres | DCE | Stimulants | Yes | Functioning, side effects, process related, costs |
*Patient participants only.
†31% African American or Hispanic.
‡Approximate percentage.
§VAS was used as a training exercise.
¶Largest age group 50–59 years.
**Choice-format trade-off questions.
CA, conjoint analysis; DCE, discrete choice experiment; PC, pairwise comparison; SG, standard gamble; TTO, time trade-off; VAS, visual analogue scale; WTP, willingness to pay.